Skip to main content

Table 2 Association between TERT promoter mutations and clinicopathologic features in 222 patients with well-differentiated thyroid carcinoma

From: Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

 

TERT promoter mutations

 

Absent (n = 210)

Present (n = 12)

p-value

Age (mean years)

45.5 ± 13.3

55.0 ± 11.8

0.017

Gender

   

 Female

164 (94.8 %)

9 (5.2 %)

0.801

 Male

46 (93.9 %)

3 (6.1 %)

Tumor size (mean mm)

14.8 ± 12.5

31.9 ± 22.9

0.043

Histologic types

   

 Aggressive varianta)

18 (75.0 %)

6 (25.0 %)

<0.001

 Less-aggressive variant

192 (97.0 %)

6 (3.0 %)

Pathologic T stage

   

 pT 1–2

97 (99.0 %)

1 (1.0 %)

0.014

 pT 3–4

113 (91.1 %)

11 (8.9 %)

Extrathyroidal extension

   

 Absent

105 (98.1 %)

2 (1.9 %)

0.035

 Present

105 (91.3 %)

10 (8.7 %)

Pathologic N stage

   

 pN0

105 (99.1 %)

1 (0.9 %)

0.011

 pN1

105 (91.3 %)

10 (8.7 %)

Lateral lymph node metastasis

   

 Absent

166 (98.8 %)

2 (1.2 %)

<0.001

 Present

43 (82.7 %)

9 (17.3 %)

Distant metastasis

   

 Absent

192 (100 %)

0

<0.001

 Present

18 (60.0 %)

12 (40 %)

AJCC stage

   

 I-II

120 (100 %)

0

<0.001

 III-IV

90 (88.2 %)

12 (11.8 %)

BRAF V600E mutation

   

 Absent

62 (95.4 %)

3 (4.6 %)

0.738

 Present

148 (94.3 %)

9 (5.7 %)

  1. a)Aggressive variant includes 21 tall cell, 1 columnar cell, and 1 diffuse sclerosing variant of papillary carcinoma and 1 widely invasive follicular carcinoma